Frank B. Furnari
Total Page:16
File Type:pdf, Size:1020Kb
CURRIULUM VITAE Frank B. Furnari Work Address: Ludwig Institute for Cancer Research & University of California, San Diego CMM-E, Room 3053 9500 Gilman Drive La Jolla, CA 92093-0660 Phone: (858) 534-7809 (lab), -7819 (office) Fax: (858) 534-7750 e-mail: [email protected] Date and Place of Birth: May 30, 1964, Queens, New York Education: B.A. awarded: May, 1985 in Biology, Hofstra University, Hempstead, New York Ph.D. awarded: January, 1993 in Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina Professional History: 1987-1993: Graduate student, Microbiology and Immunology, University of North Carolina: Chapel Hill, NC. 2/93-7/00: Postdoctoral fellow, Ludwig Institute for Cancer Research & University of California, San Diego; La Jolla, CA. 8/00-4/07: Assistant Investigator and Head of the Section of Human Carcinogenesis: Ludwig Institute for Cancer Research-San Diego 4/07-11/11: Associate Investigator and Head of the Section of Human Carcinogenesis: Ludwig Institute for Cancer Research-San Diego 11/11-6/15: Senior Investigator and Head of the Section of Human Carcinogenesis: Ludwig Institute for Cancer Research-San Diego 6/15-12/15: Senior Investigator and Head Laboratory of Tumor Biology: Ludwig Institute for Cancer Research-San Diego 1/16-present: Member and Head Laboratory of Tumor Biology: Ludwig Institute for Cancer Research-San Diego 7/01-6/07: Assistant Adjunct Professor, UCSD Department of Medicine 7/07-10/11: Associate Adjunct Professor, UCSD Department of Medicine 3/01-9/05: Associate Member, UCSD Moores Cancer Center 10/05-present: Participating Member, UCSD Moores Cancer Center 7/10-present: Faculty member T32 GM008666: Basic and Clinical Genetics 9/11-present: Supervisory committee T32 CA009523: Growth Regulation and Oncogenesis 9/15-present: Faculty member T32 CA121938: Cancer Cell Biology 11/11-present: Professor (tenured), UCSD Department of Pathology 11/11-present: Head of Neuro-oncology Research in the Division of Neuropathology, UCSD Honors and Awards: 11/92 Travel Grant, American Association for Cancer Research 8/92 Travel Grant, NIH 1991 Travel Grant, University of North Carolina 1994-1997 The Robert Steel Foundation for Pediatric Cancer Research Fellowship 1999 AACR Young Investigator Award 1999 Pediatric Brain Tumor Foundation Travel Award 2001 Kimmel Faculty Scholar Award 2002 V Foundation Scholar Award 2005 Goldhirsh Foundation Grant 2010 Society for Neuro-Oncology Award for Excellence in Adult Basic Research 2011 Society for Neuro-Oncology Award for Excellence in Translational Research 2011 Rubinstein Achievement in Neuropathology Award 2012 European Association for Cancer Research- Molecular Insights into Invasion and Drug Resistance- proffered paper award 2016 MD Anderson: 2016 Deborah M. Richman Lecture 2016 Selected co-chair 2017 Society for Neuro-Oncology annual meeting 2017 Society for Neuro-Oncology Scientific program co-chair Publications: Furnari, F. B., Adams, M. D., and Pagano, J. S. Regulation of the Epstein-Barr Virus (EBV) DNA Polymerase Gene. J. Virol 66:2837-2845,1992. Furnari, F. B., Adams, M. D. and Pagano, J. S. Novel Processing of the 3' End of the EBV DNA Polymerase mRNA. PNAS 90:378-82, 1993. Furnari, F. B., Quinlivan, E. B., Kenney, S., and Pagano, J. S. RAZ, An Epstein-Barr Virus Transdominant Repressor That Modulates The Viral Reactivation Mechanism. J. Virol 68: 1827- 1836, 1994. Arap, W., Nishikawa, R., Furnari, F. B., Cavenee, W. K., Huang, H-J. S. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995. Nishikawa, R., Furnari, F. B., Ling, H., Arap, W., Berger, M. S., Cavenee, W. K., Huang, H-J. S. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res 55: 1941-1945, 1995. Furnari, F. B., Lin, H., Huang, H.-J. S., Cavenee, W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. PNAS 94: 12479-12484, 1997. Robertson, G. P., Furnari, F. B., Miele, M. E., Glendening, M. J., Welch, D. R., Fountain, J. W., Lugo, T. G., Huang, H.-J. S., Cavenee, W. K. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. PNAS 95: 9418-9423, 1998. Carethers, J. M., Furnari, F. B., Zigman, A. F., Lavine, J. E., Jones M. C., Graham, G. E., Teebi, A. S., Huang, H.-J. S., Ha, H. T., Chauhan, D. P., Chang, C. L., Cavenee, W. K., Boland, C. R. Absence of PTEN/MMAC1 Germline mutations in sporadic Bannayan-Riley-Ruvalcaba Syndrome. Cancer Res. 58: 2724-2726, 1998. Furnari, F. B., Huang, H.-J. S., Cavenee, W. K. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 58: 5002-5008, 1998. Wick, W., Furnari, F. B., Naumann, U., Cavenee, W. K., Weller, M.W. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18:3936-3943, 1999. Bogler, O., Furnari, F. B., Kindler-Roehrborn, A., Sykes, V. W., Yung, R., Huang, H.-J. S., Cavenee, W. K. SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro-Oncology 2:6-15, 2000. Reiss, K., Wang, J.-Y., Romano, G., Furnari, F. B., Cavenee, W. K., Morrione, A., Tu, X., Baserga, R. IGF-1 receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 19:2687-2694, 2000. Fan, X., Furnari, F. B., Cavenee, W. K., Castresana, J. S. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. Int J Cancer. 18:1023-1026, 2001. Chuenkova, M. V., Furnari, F. B., Cavenee, W. K., Pereira, M. A. Trypanosoma cruzi trans- sialidase: A potent and specific survival factor for human schwann cells via phosphatidylinositol 3-kinase/Akt signaling. PNAS 98: 9936-9941, 2001. Klingler-Hoffmann, M, Fodero-Tavoletti, M. T., Mishima, K., Narita, Y., Cavenee, W. K., Furnari, F. B., Huang, H.-J. S., Tiganis, T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. JBC 276: 46313-46318, 2001. De Smet, C., Nishimori, H., Furnari, F. B., Bogler, O., Huang, H.-J. S., Cavenee, W. K. A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. J. Neurochem. 81:1-14, 2002 Narita, Y., Nagane, M., Mishima, K., Huang, H.-J. S., Furnari, F. B., Cavenee, W. K. Mutant Epidermal Growth Factor Receptor signaling down-regulates p27 through activation of the Phosphatidylinositol 3-kinase/Akt pathway in Glioblastomas. Cancer Res. 62: 6764-6769, 2002. Schmidt, M. H. H., Furnari, F. B., Cavenee, W. K., Bogler, O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. PNAS 100: 6505-6510, 2003. The HGCP/CGAP Consortium. The Generation and Utilization of a Cancer Oriented Representation of the Human Transcriptome, Using Expressed Sequence Tags. PNAS 100: 13418-13423, 2003. Shah, J. V., Botvinick, E., Bonday, Z., Furnari, F., Berns, M., Cleveland, D. W. Dynamics of centromere and kinetochore proteins: implications for checkpoint signaling and silencing. Current Biology 14: 942-952, 2004. Schmidt, M. H. H., Hoeller, D., Yu, J., Furnari, F. B., Cavenee, W.K., Dikic, I., Bogler, O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl- SETA/CIN85 complex. MCB 24: 8981-8993, 2004. Nishikawa, R., Suigiyama, T., Narita, Y., Furnari, F., Cavenee, W. K., Matsutani, M. Immunohistochemical analysis of the mutant epidermal growth factor, DEGFR, in glioblastoma. Brain Path, 21: 53-56, 2004. Okumura, K., Zhao, M., DePinho, R.A., Furnari, F.B., Cavenee, W.K. Cellular Transformation by the MSP58 Oncogene is Inhibited by its Physical Interaction with the PTEN Tumor Suppressor. PNAS 102: 2703-2706, 2005. Gao, T., Furnari, F., Newton, A.C. PHLPP: a Novel Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor Growth. Molecular Cell 18: 13-24, 2005. Perera, R. m., Narita, Y., Furnari, F. B., Tavarnesi, M. L., Luwor, R. B., Burgess, A. W., Stockert, E., Jungbluth, A. A., Old, L. J., Cavenee, W. K., Scott, A. M., Johns, T. G. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity. Clin Cancer Res 11: 6390- 6399, 2005. Carrasco, D. R., Fenton, T., Protopopova, M., Sukhdeo, K., German, M., You, M., Divicio, D., Nogueira, C., Stommel, J., Fletcher, C., Hornick, J. L., Cavenee, W. Furnari, F., DePinho, R. A. PTEN and Ink4a/Arf tumor suppressors maintain a myelolymphoid hematopoietic compartment and cooperate to constrain histocytic sarcoma development. Cancer Cell, 9:379-90, 2006. Sok, J. C., Coppelli, F. M., Thomas, S. M., Lango, M, N., Xi, S., Hunt, J. L., Freilino, M. L., Graner, M. W., Wikstrand, C. J., Bigner, D. D., Gooding, W. E., Furnari, F. B., Grandi, J. R. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. Clinical Cancer Research, 12: 5064-5073, 2006. Okumura, K., Mendoza, M., Bachoo, R. M., DePinho, R. A., Cavenee, W. K., Furnari, F. B. PCAF regulates the PI3-kinase signaling pathway by acetylating PTEN. JBC, 281: 26562-26568, 2006 (paper of the week). Johns, T. G., Perera R. M., Vernes, S. C., Vitali A. A., Cao, D. X., Cavenee, W. K., Scott, A. M., Furnari F. B. The Efficacy of EGFR-Specific Antibodies Against Glioma Xenografts is Influenced by Receptor Levels, Activation Status and Heterodimerization. Clinical Cancer Research, 13: 1911-1925, 2007 (cover of issue). Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Zachary E. Brewer Z. E., Cavenee, W. K., Furnari, F. B*, White, F. M.* Quantitative Analysis of EGFRvIII Cellular Signaling Networks Reveals a Novel Combinatorial Therapeutic Strategy for Glioblastoma.